Evolution of plasma homovanillic acid (HVA) levels during treatment in schizo-affective disorder

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 24, Issue 8, 2000, Pages 1319-1328

  Galinowski, Andre ^a   Castelnau, Christian ^a   Spreux Varoquaux, Odile ^b   Bourdel, Marie Chantal ^a   Olie, Jean Pierre ^a   Loo, Henri ^a   Poirier, Marie France ^a  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b Pharmacology Department   (France)

Author keywords

Drug treatment; Homovanillic acid; Schizo affective disorder

Indexed keywords

CHLORPROMAZINE; CLOMIPRAMINE; HOMOVANILLIC ACID; LITHIUM;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DOPAMINE METABOLISM; EVOLUTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PROGNOSIS; REMISSION; SCHIZOIDISM; SCHIZOPHRENIA;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOMIPRAMINE; DRUG THERAPY, COMBINATION; FEMALE; HOMOVANILLIC ACID; HUMANS; LITHIUM; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS;

EID: 0033696725     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(00)00140-8     Document Type: Article

References (23)

1. Relationship between response to IV clomipramine, plasma drug levels, platelet 5-HT, plasma 5-HIAA and HVA in depressed patients
2. Homovanillic acid measurement in clinical research: A review of methodology
3. Lithium in combination with perphenazine : Effect on plasma monoamine metabolites
4. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation
5. Acute effects of lithium on catecholamine, serotonin and their major metabolites in discrete brain regions
6. The positive and negative syndrome scale (PANSS) for schizophrenia
7. Neurochemistry and neuroendocrinology of schizophrenia: A selective review
8. Biological studies of schizoaffective disorders
9. A new depression scale designed to be sensitive to change
10. Parkinson's disease and the Columbia scale
11. Initial monoamine oxidase. A inhibition by moclobemide does not predict the therapeutic response in patients with major depression
12. A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia
13. Psychotic (delusional) major depression : Should it be included as a distinct syndrome in DSM-IV?
14. Pretreatment plasma homovanillic acid in schizophrenia and schizoaffective disorder: The influence of demographic variables and the inpatient drug- free period
15. A rating scale for extrapyramidal side effects
16. Diurnal variation in plasma homovanillic acid: Not a renal phenomenon
17. Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia
18. Long-term outcome of major psychoses, I : Schizophrenia and affective disorders compared with psychiatrically symptom-free surgical conditions
19. Neuropsychological profile linked to low dopamine: In Alzheimer's disease, major depression, and Parkinson's disease
20. The ICD-10 classification of mental and behavioural disorders: Diagnostic criteria for research